A symptom-based approach to pharmacologic management of fibromyalgia

Nature Reviews Rheumatology

Volumn 5, Issue 4, 2009, Pages 191-199

  Boomershine, Chad S ^a   Crofford, Leslie J ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MANAGEMENT; FIBROMYALGIA; HOSPITALIZATION; HUMAN; PATHOPHYSIOLOGY; REVIEW;

DISEASE MANAGEMENT; FIBROMYALGIA; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 67650486524     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.25     Document Type: Article

References (62)

1. Wolfe, F., Ross, K., Anderson, J., Russell, I. J. & Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 38, 19-28 (1995).
2. Wolfe, F. & Michaud, K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with ibromyalgia. J. Rheumatol. 31, 695-700 (2004).
3. Middleton, G. D., McFarlin, J. E. & Lipsky, P E. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum. 37, 1181-1188 (1994).
4. Berenson, A. Drug approved. Is disease real? (online 14 January 2008) [www.nytimes. com/2008/01/14/health/14pain.html] (accessed 29 September 2008).
5. Carville, S. F. et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann. Rheum. Dis. 67, 536-541 (2008).
6. Wolfe, F. et al. The American College of Rheumatology 1990 criteria for the classification of fibromyaglia. Arthritis Rheum. 33, 160-172 (1990).
7. Bennett, R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics, and uses. Clin. Exp. Rheumatol. 23, S154-S162 (2005).
8. Wolfe, F. et al. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J. Rheumatol. 27, 1989-1999 (2000).
9. Zachrisson, O. et al. A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J. Psychosom. Res. 52, 501-509 (2002).
10. Boomershine, C. S. et al. Five visual analogue scales quantify global disease severity and identify clinically significant symptoms in fibromyalgia syndrome. Arthritis Rheum. 58, S686-S687 (2008).
11. Katz, R. S., Wolfe, F. & Michaud, K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 54, 169-176 (2006).
12. Slotkoff, A. T., Radulovic, D. A. & Clauw, D. J. The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. Scand. J. Rheumatol. 26, 364-367 (1997).
13. Boomershine, C. S. First pregabalin and now duloxetine for fibromyalgia syndrome: closer to a brave new world? Nat. Clin. Pract. Rheumatol. 4, 636-637 (2008).
14. Hindmarch, I., Dawson, J. & Stanley, N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 28, 187-193 (2005).
15. Arnold, L. M. et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 56, 1336-1344 (2007).
16. Stahl, S. M., Grady, M. M., Moret, C. & Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10, 732-747 (2005).
17. Milnacipran package insert [http://www.fda.gov/cder/foi/label/2009/022256lbl.pdf] (accessed 30 January 2009).
18. Pregabalin package insert [http://www.fda.gov/ cder/foi/label/2007/021446s010lbl.pdf] (accessed 30 January 2009).
19. Arnold, L. M. et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am. J. Med. 112, 191-197 (2002).
20. Boyer, E. W. & Shannon, M. The serotonin syndrome. N. Engl. J. Med. 352, 1112-1120 (2005).
21. Ugeyler, N., Hauser, W. & Sommer, C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 59, 1279-1298 (2008).
22. Nishishinya, B. et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 47, 1741-1746 (2008).
23. Simpson, D. A. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J. Clin. Neuromuscul. Dis. 3, 53-62 (2001).
24. Kumar, R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 68, 1803-1839 (2008).
25. Schwartz, T. L. et al. Modafinil treatment for fatigue associated with fibromyalgia. J. Clin. Rheumatol. 13, 52 (2007).
26. Pachas, W. N. Modafinil for the treatment of fatigue in fibromyalgia. J. Clin. Rheumatol. 9, 282-285 (2003).
27. Schaller, J. L. & Behar, D. Modafinil in fibromyalgia treatment. J. Neuropsychiatry Clin. Neurosci. 13, 530-531 (2001).
28. Glass, J. M. Fibromyalgia and cognition. J. Clin. Psychiatry 69 (Suppl. 2), S20-S24 (2008).
29. Culpepper, L. & Mattingly, G. A practical guide to recognition and diagnosis of ADHD in adults in the primary care setting. Postgrad. Med. 120, 16-26 (2008).
30. Rostain, A. L. Attention-deficit/hyperactivity disorder in adults: evidence-based recommendations for management. Postgrad. Med. 120, 27-38 (2008).
31. Wallace, D. J. & Gotto, J. Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. Semin. Arthritis Rheum. 37, 256-259 (2008).
32. Moldofsky, H., Scarisbrick, P, England, R. & Smythe, H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom. Med. 37, 341-351 (1975).
33. Moldofsky, H. & Scarisbrick, P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom. Med. 38, 35-44 (1976).
34. Netzer, N. C., Stoohs, R. A., Netzer, C. M., Clark, K. & Strohl, K. P. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann. Intern. Med. 131, 485-491 (1999).
35. Yunus, M. B. & Aldag, J. C. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ 312, 1339 (1996).
36. Walters, A. S. Toward a better definition of the restless legs syndrome. Mov. Disord. 10, 634-642 (1995).
37. Holman, A. J. & Myers, R. R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 52, 2495-2505 (2005).
38. Holman, A. J. Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia. J. Clin. Rheumatol. 9, 277-279 (2003).
39. Pramipexole package insert [http://www.fda. gov/medwatch/safety/2006/Nov PIs/Mirapex PI.pdf] (accessed 30 January 2009).
40. Ropinirole package insert [http://www.fda.gov/ medwatch/SAFETY/2005/MAY PI/Requip PI.pdf] (accessed 30 January 2009).
41. Morgenthaler, T. et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine report. Sleep 29, 1415-1419 (2006).
42. Becker, P. M. Pharmacologic and nonpharmacologic treatments of insomnia. Neurol. Clin. 23, 1149-1163 (2005).
43. Moldofsky, H. The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr. 13 (Suppl. 5), 22-26 (2008).
44. Moldofsty, H. & Lue, F. A. The relationship of alpha and delta EEG frequencies to pain and mood in 'fibrositis' patients treated with chlorpromazine and L-tryptophan. Electroencephalogr. Clin. Neurophysiol. 50, 71-80 (1980).
45. Cohrs, S. et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl.) 174, 421-429 (2007).
46. Hidalgo, J., Rico-Villademoros, F. & Calandre, E. P. An open-label study of quetiapine in the treatment of fibromyalgia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 71-77 (2007).
47. Russell, I. J. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 60, 299-309 (2009).
48. White, K. P, Nielson, W. R., Harth, M., Ostbye, T. & Speechley, M. Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample. J. Rheumatol. 29, 588-594 (2002).
49. Ratcliffe, G. E., Enns, M. W., Belik, S. L. & Sareen, J. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clin. J. Pain 24, 204-210 (2008).
50. Russell, I. J. et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136, 432-444 (2008).
51. Sayar, K., Aksu, G., Ak, I. & Tosun, M. Venlafaxine treatment of fibromyalgia. Ann. Pharmacother. 11, 1561-1565 (2003).
52. Clauw, D. J. Pharmacotherapy for patients with fibromyalgia. J. Clin. Psychiatry 69 (Suppl. 2), 25-29 (2008).
53. Goldenberg, D., Mayskiy, M., Mossey, C., Ruthazer, R. & Schmid, C. A randomized, double- blind crossover trial of fluoxetine and amitripty line in the treatment of fibromyalgia. Arthritis Rheum. 39, 1852-1859 (1996).
54. Samborski, W., Lezanska-Szpera, M. & Rybakowski, J. K. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 37, 168-170 (2005).
55. Saletu, B. et al. Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database. Neuropsychobiology 51, 148-163 (2005).
56. See, S. & Ginzburg, R. Choosing a skeletal muscle relaxant. Am. Fam. Physician 78, 365-370 (2008).
57. Tofferi, J. K., Jackson, J. L. & O'Malley, P G. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 51, 9-13 (2004).
58. Wolfe, F., Zhao, S. & Lane, N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 44, 2451-2455 (2001).
59. Bennett, R. M. et al. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/ acetaminophen. Arthritis Rheum. 53, 519-527 (2005).
60. Cicero, T. J. et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 57, 7-22 (1999).
61. Abeles, M., Solitar, B. M., Pillinger, M. H. & Abeles, A. M. Update on fibromyalgia therapy. Am. J. Med. 121, 555-561 (2008).
62. Goldenberg, D. L. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract. Res. Clin. Rheumatol. 21, 499-511 (2007).